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Abstract:  
 
Genomic sequences able to form guanine quadruplexes (G4) are found in oncogene promoters, in 
telomeres and in 5’ and 3' untranslated regions as well as introns of messenger RNAs. These regions are 
potential targets for drugs designed to treat cancer. In the present work, we present the design and 
syntheses of ten new phenantroline derivatives and characterization of their interactions with G4-forming 
oligonucleotides. We evaluated ligand-induced stabilization and specificity and selectivity of ligands for 
various G4 conformations using FRET-melting experiments. We investigated the interaction of compound 
1a, which combined the greatest stabilising effect and specificity for G4, with human telomeric sequences 
using FRET, circular dichroism and ESI-MS. In addition, we showed that compound 1a interferes with the 
G4 helicase activity of Saccharomyces cerevisiae Pif1. Interestingly, compound 1a was significantly more 
cytotoxic toward two human leukemic cell lines than to normal human blood mononuclear cells. These novel 
phenantroline derivatives will be a starting point for further development and optimization of potent G4 
ligands that have potential as anti-cancer agents. 
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Introduction 
G-quadruplexes (G4) are secondary structures adopted by guanine-rich nucleic acids. G4 
structures consist of a planar arrangement of two or more guanine quartets stabilized by cations (typically 
potassium or sodium) [1]. These structures have been detected in human cells using structure-specific 
antibodies [2,3], and computational studies have identified regions with the potential to form such structures 
in organisms such as the yeast Saccharomyces cerevisiae and human [4,5]. More than 370,000 sequences 
with potential to form G-quadruplex structures have been identified in the human genome [6,7]. Sequences 
prone to form G4 in human genome are found in key regions such as gene promoters, untranslated regions 
of messenger RNAs, telomeres, immunoglobulin switch regions, and in DNA replication origins [8]. 
Therefore, G-quadruplexes are likely involved in numerous biological processes such as transcription, 
translation, cell aging, and diseases such as cancer [9]. 
A number of proteins have been shown to interact with G-quadruplexes in vitro (for review [10]). 
Helicases such as Fanconi anaemia group J protein (Fanc J), Bloom syndrome protein (BLM), Werner 
syndrome protein (WRN), and Petite Integration Frequency 1 (PIF1) can unwind G4 structures formed by 
different sequences. Increases in cancer risk and/or genomic instability are associated with mutations that 
impair the function of these motor-like proteins [11]. 
Small molecules that specifically target G-quadruplexes have potential as anti-cancer drugs. It has 
been postulated that ligands that stabilize G-quadruplex structures will disturb or impede the expression of 
oncogenes containing one or more G4 motifs in their promoters. This hypothesis is supported by the fact 
that the potential to form G4 is higher in the promoters of oncogenes than in tumour suppressor genes [12]. 
Ligands that stabilize G-quadruplexes formed by the human telomeric DNA may also inhibit growth of cancer 
cells. Chromosomes end consist in 3’ single-stranded TTAGGG repeats. These overhangs adopt G4 
structures that inhibit telomerase activity in vitro. Telomerase, a reverse transcriptase that elongates 
telomeres, is overexpressed in most human cancers [13]. G4 stabilizing compounds may also promote 
telomere uncapping, which triggers the DNA damage response [14]. Both inhibition of telomere elongation 
and the DNA damage response can trigger a proliferation arrest resulting in anti-cancer activity. 
Numerous G4 ligands belonging to different chemical families have been synthesized. Most of these 
ligands have scaffolds that consist of a planar aromatic core and chemical substituents that bear positives 
charges [15]. A large number of small heterocyclic molecules have been synthesized and evaluated for their 
ability to interact with G-quadruplexes [16]. Among them are the 1,10-phenanthroline derivatives, such as 
PhenDC3 and its structural analogues I, tetra-amino-phenanthroline II, K35, and phenanthroline-2,9-
bistriazole III (Figure 1) [17–28]. These compounds have been investigated for their capacity to bind and 
stabilize various G4 topologies and for their selectivity for G-quadruplex versus duplex structures.  
The extended planar aromatic structure of the 1,10-phenanthroline scaffold provides a basis for 
efficient  stacking interactions with G-quartets. Here, we designed and synthesized ten new 
phenanthroline derivatives 1a-j. We hypothesized that substitution with diaminobenzyl moieties in position 
2 and 9 could lead to more potent G4 ligands in term of selectivity by increasing the aromatic surface and 
by enhancing aqueous solubility. This strategy has previously been reported for the design and synthesis 
of the disubstituted phenyl bis-oxazole IV (Figure 1) [29].  We reasoned that the extended aromatic structures 
of the diaminobenzyl groups would provide a basis for  stacking interactions with the G-quartets and 
that the length of the amine side chains could influence the stabilizing potential of the ligands. We evaluated 
ligand-induced stabilization, specificity, and selectivity of the newly synthesized phenanthroline derivatives 
for various G4 topologies through FRET-melting experiments. We further investigated the stoichiometries 
and the binding modes of the most potent derivatives with human telomeric sequences and determined the 
cytotoxicity against two different leukaemia cell lines and normal human peripheral blood mononuclear cells. 
Finally, we tested the ability of the ligands to interfere with the G4 unwinding activity of the Pif1 helicase 
from S. cerevisiae. 
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Results and Discussion 
Chemistry 
The reported 2,9-bis[(substituted-aminomethyl)phenyl]-1,10-phenanthroline derivatives 1a-i were 
synthesized from the commercially available 2,9-dichloro-1,10-phenanthroline (Schemes 1 and 2). The bis-
[2,9-(formylphenyl)]-1,10-phenanthrolines 2a-c were easily prepared by a direct double-Suzuki-Miyaura 
cross-coupling reaction of 2,9-dichloro-1,10-phenanthroline with 2-, 3- or 4-formylphenylboronic acid 
performed in the presence of Pd(PPh3)4 as a catalyst, and in the presence of potassium (or sodium) 
carbonate as the base [30,31]. The structure of 2b was established by X-ray crystallography, IR, and 1H and 
13C NMR data (Figure 2). Reaction of primary amines with 2a-c gave the di-imines 3a-i, which were reduced 
into the 2,9-bis[(substituted-aminomethyl)phenyl]-1,10-phenanthrolines 1a-i using sodium borohydride in 
methanol as previously described [17]. The mono-substituted structural analogues of 1a-i were obtained by 
substituting the 1,10-phenanthroline core with an aminomethyl)phenyl moiety substituted only at position 2. 
Using this singly substituted core, 2-{4-[(3-dimethylaminopropyl)aminomethyl]phenyl}-1,10-phenanthroline 
1j (Scheme 2) was obtained. The first attempts to synthesize the intermediate aldehyde 2d by coupling 2-
chloro-1,10-phenanthroline with 4-formylphenylboronic acid or 4-formylphenyl MIDA boronate failed. The 
mono-aldehyde 2d was prepared using 4-formylphenylboronic acid pinacol ester under mild conditions in 
the presence of Pd(PPh3)4 and cesium carbonate as previously described [32]. Condensation of 3-
(dimethylamino)-1-propylamine with aldehyde 2d led to the imine 3j, which was then converted to the 2-{4-
[(3-dimethylaminopropyl)aminomethyl]phenyl}-1,10-phenanthroline 1j by reduction with NaBH4 as 
described above. These phenanthroline compounds 1a-j were then converted into their ammonium oxalate 
salts by treatment with oxalic acid in refluxing isopropanol. Table 1 summarizes the physical properties of 
the 1a-j oxalates. 
 
Screening assays 
To evaluate the ability of the synthetized compounds to interact with G4, we used three different 
FRET-melting experiments to determine; (i) ligand (1a-j) induced stabilization of a given G4 sequence, (ii) 
preferences for G4 over duplex, and (iii) specificity towards a particular G4 sequence. We first assessed the 
effect of increasing concentrations of ligands 1a-j on the thermal stability of the G4 conformation adopted 
by the F21T DNA oligonucleotide (Supplementary Table 1), derived from the human telomere sequence, in 
K+ and in Na+ conditions. G4-forming oligonucleotides adopt various topologies in vitro depending on the 
length and sequence composition, the ionic environment, and the sample preparation. In K+, F21T adopts a 
mixture of G4 conformations containing an antiparallel and a 3+1 hybrid type topologies; in Na+ conditions, 
F21T forms an antiparallel G4 conformation. Each of the synthetized compounds 1a-j stabilized F21T in 
both K+ (10 mM supplemented with 90 mM LiCl) and Na+ (100 mM) conditions, although to different extents 
(Supplementary Figure S1). This stabilization (T1/2) was calculated from comparison of temperature of half 
denaturation (T1/2) of the fluorescently labelled oligonucleotide in the presence or absence of the ligand. The 
well-characterized G-quadruplex ligand phenanthroline PhenDC3 [17] (Figure 1) was used in these tests as 
a positive control. Our results showed that ligands 1a-j were more stabilizing in K+ conditions than in Na+ 
conditions, and two ligands (compounds 1a and 1b) induced the highest increase in F21T thermal stability 
in both conditions (Figure 3 and Table 2). The least stabilizing compounds were derivatives 1h, 1i, and 1j.  
As these new tested ligands 1a-j share the same phenanthroline core and differ in the nature and 
the position of the polyaminoalkyl chain substitutions, we tried to infer information on the structure-activity 
relationship (SAR) of these new synthetic compounds. The phenanthrolines 1a-d, which are disubstituted 
with polyaminoalkyl chains on position 4 of the benzyl moieties, effectively stabilized the F21T structure. 
The T1/2 ranged from 10.4 to 14.9 °C for the 4-substituted phenyl compounds 1a-d, and the T1/2 of 
phenanthrolines 1e-g substituted in position 3 of the phenyl moieties ranged from 9.4 to 11.6 °C. When the 
benzyl moieties were modified with aminoalkyl chains on position 2 (compounds 1h and 1i), T1/2 values 
ranged from 5.3 to 7.7 °C. Interestingly, in terms of average values, ligands bearing a methylpiperazine 
moiety on the aminoalkyl side chains of the benzyl could be generally considered slightly more efficient 
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stabilizers of F21T than the corresponding dimethylamino, pyrrolidine, or morpholine analogues in each 
subseries substituted on positions 2, 3, or 4. For example, compound 1b stabilized F21T better than 
structural analogues 1c or 1d in the 4-substituted position. In the subseries in which the polyaminoalkyl side 
chain was anchored in position 3 of the benzyl ring, the piperazine substituted phenanthroline 1f seemed to 
be slightly more stabilizing than derivatives 1e and 1g. The same observation could be found for substitution 
in position 2: T1/2 was 5.3 °C for compound 1h versus 7.7 °C for 1i. Moreover, the mono-substitution of the 
phenanthroline core with a polyaminoalkylbenzyl substituent (compound 1j) led to a decrease in the G4 
stabilization (T1/2 = 5.9 °C) in comparison with its disubstituted analogue 1a (T1/2 = 14.0 °C). Finally, 
compounds 1a-j were found to be less effective F21T stabilizers than reference compound PhenDC3: i.e., 
the T1/2 for PhenDC3 was noticed at 21.8 °C whereas T1/2 values for phenanthrolines 1a-j ranged from 
5.3 to 14.9 °C.  
To assess the ligand selectivity for G4, we performed a FRET-melting experiment in the presence of 
a self-complementary double-stranded DNA competitor ds26 (5'd-
CAATCGGATCGAATTCGATCCGATTG3'). For this experiment, we excluded compounds 1h, 1i, and 1j as 
these ligands resulted in less than 10 °C of F21T stabilization in K+ conditions. We monitored F21T melting 
in the presence of 1 µM compounds 1a-g and of an excess of ds26 as competitor (15 or 50 equivalents 
compared to F21T). No significant effect was observed for F21T thermal stability after addition of a 15 
equivalent excess of competitor (3 µM) in the presence of the ligands tested, except for 1b (Figure 4 and 
Table 2). Higher ds26 concentrations (15 µM - 50 equivalent excess) led to a decrease in ∆Tm for 
compounds 1b and 1f. In contrast, ds26 had no impact on the stabilizing effects of 1c and 1e and only 
marginally affected the stabilizing abilities of 1a, 1d, and 1g.  
The slight decrease in F21T thermal stability obtained in the presence of a large excess of ds26 
reflects a fair selectivity towards the G4 structure. To confirm this observation we performed circular 
dichroism (CD) melting experiments. CD melting analysis showed that 1a stabilised both 22AG and c-myc 
(unlabelled; Supplementary Table 2), but had little or no effect on ds26 melting temperature. 
We estimated an index of selectivity S for each compound by calculating the ratio of F21T ΔT1/2 in 
the presence of ligand with 3 µM ds26 and F21T ΔT1/2 in the presence of ligand without competitor. Our 
results showed that all derivatives displayed selectivity toward F21T in K+ conditions with S between 0.82 
and 0.93 (Table 2). When the stabilization ability and the selectivity index criteria were considered, 
compound 1a was the most promising G4 ligand in this newly synthetized series.   
To determine whether this promising phenanthroline 1a could stabilize other G4-forming sequences, 
we performed FRET-melting assays with G-rich DNA oligonucleotides (Supplementary Table 1) that are 
known to adopt various G4 topologies [40] including parallel-stranded G4s such as F25cebT, derived from 
the human minisatellite sequence [41], and FcmycT, derived from a human oncogene promotor [42]; and anti-
parallel G4s with two G-quartets such as FtbaT the thrombin binding aptamer sequence [43], and Fbom17T, 
a sequence derived from the Bombyx mori telomeres [44]. We also used F21RT, an RNA oligonucleotide 
derived from the human telomere sequence, which folds into a parallel G4, and FctaT, a DNA 
oligonucleotide which is a mutant variant derived from the DNA human telomeric sequence that adopts an 
anti-parallel G4 conformation [45]. Finally, we used the DNA oligonucleotide FdxT, a non-G4-forming control 
sequence, which folds onto an intramolecular duplex.  For technical reasons, we used the same salt 
conditions for all the sequences tested (K+ conditions) with the exception of the F21RT. The potassium 
concentration for analysis of F21RT was 1 mM instead of 10 mM:  at a 10 mM potassium concentration, the 
thermal stability of the G4 adopted by F21RT is too high to allow the measurement of the stabilization 
induced by a given ligand. Since G-quadruplex stability is cation concentration dependent, decreasing the 
potassium concentration enabled us to follow the ligand effect on this RNA sequence [46]. As shown in Figure 
5, ligand 1a preferentially stabilized the RNA (F21RT) and DNA (F21T) human telomeric sequences. 
Phenanthroline 1a stabilized the mutated variant of the telomeric sequence (FctaT), the telomeric sequence 
from B. mori (Fbom17T), and the thrombin binding aptamer sequence (FtbaT) to a lesser extent than it did 
F21T. Compound 1a did not stabilize the parallel DNA G4 structures adopted by F25cebT and FcmycT. 
These G4 forming sequences both possess three propeller loops (including a very long one for F25cebT).  
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Interestingly, the CD melting experiments showed greater stabilization of unlabelled cmyc 
oligonucleotide than did the FRET-melting experiments (Supplementary Table 2). Two factor may explain 
this apparent discrepancy: i) different oligonucleotides are used for these experiments: in FRET-melting we 
used a dual-labelled c-myc sequence while in CD we used unlabeled c-myc oligonucleotide; ii) 
oligonucleotide and compound concentrations are different, due to different sensibilities of the techniques. 
This observation also points out the necessity of performing complementary experiments using unlabelled 
sequences in addition to the FRET-melting screening assay. All of our results, however, suggest that 
compound 1a preferentially stabilizes G4 structure adopted by the human telomeric sequences F21T and 
F21RT relative to those conformations adopted by the other oligonucleotides tested.  
PhenDC3 has better G4 versus duplex selectivity than does 1a (Table 2). In contrast, the FRET-
melting assay showed that 1a only preferentially stabilized the human telomeric sequences which suggests 
a better target specificity. Other G4 ligands, such as 360A and pyridostatin, interact differently with the same 
panel of oligonucleotides [40]. This finding emphasizes that the combination of different structural elements 
are critical for G4-ligand interactions resulting in various degrees of selectivity and specificity even for 
ligands that belong to the same chemical family.  
 
Interaction mode investigation 
Taken together, the FRET-melting results showed that of the newly synthesized ligands, 1a 
displayed the best stabilization and showed a preference for the human telomeric sequences with an 
excellent G4 vs. duplex selectivity. Since human telomeric sequences can adopt different G-quadruplex 
conformations depending on their length and flanking bases [37], we performed CD titration experiments 
using the 1a ligand with two different unlabelled sequences: 22AG and 24TTG (Supplementary Table 1). 
These oligonucleotides are 22 and 24 bases long, respectively.  
The obtained CD spectra collected under identical K+ conditions showed first that 22AG and 24TTG 
sequences have different CD signatures. The CD spectrum of 22AG (3 µM) in absence of ligand has two 
positive peaks around 250 nm and 290 nm and a positive shoulder around 275 nm (Figure 6a, solid black 
line). The spectrum of 24TTG (3 µM) was characterized by higher amplitude peaks than observed in the 
spectrum of 22AG. The spectrum of 24TTG had a negative peak around 240 nm and two positive peaks 
around 270 and 290 nm (Figure 6b, solid black line). Upon addition of 1 to 5 equivalents of 1a to the DNA, 
we observed the emergence of a positive peak between 260 and 265 nm in CD signatures of both 
oligonucleotides. In the case of 22AG, we observed a decrease in amplitude of the positive peaks at 290 
nm and 250 nm and the appearance of a negative peak around 240 nm upon the addition of 1a (Figure 6a, 
dashed lines).  For 24TTG, a decrease in the amplitude of the positive peak at 290 nm was observed in the 
presence of 1a (Figure 6a and 6b, dashed lines). In contrast, upon PhenDC3 addition to 24TTG, we 
observed significant changes, with a decrease in the amplitudes of the positive peak at 270 nm and the 
negative peak around 240 nm and the appearance of two new peaks, one negative peak at 265 nm and 
one positive peak at 250 nm (Supplementary Figure S2). 
PhenDC3 and 1a also induced different changes in the CD profile of the mutated variant of the 
human telomeric sequence 22CTA. Upon the addition of PhenDC3, 22CTA kept its antiparallel conformation 
as demonstrated by increased amplitudes of the positive peak around 295 nm and the negative peak around 
270 nm (Supplementary Figure S3b). In contrast, upon the addition of 1a we observed the emergence of a 
new positive peak between 260 and 265 nm and a decrease in the amplitude of the positive peak around 
295 nm. Further, the positive peak at 250 nm disappeared upon addition of 1a and a new negative peak at 
245 nm was observed. These results suggest that 1a induces a change in the conformation of a significant 
fraction of 22CTA to a parallel G4 (Supplementary Figure S3a). This is one of the rare examples of ligand 
characterized that induces a change to the parallel conformation for the human telomeric G4 forming 
sequence. [39,47,48,58] 
After confirming the interaction of 1a with human DNA telomeric G4 forming sequences using CD, 
we performed titrations by mass spectrometry to better characterize this interaction [49]. Our first goal was 
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to determine the stoichiometry of interaction between 1a and human DNA telomeric sequence. The second 
objective was to determine whether this interaction caused potassium displacement. This cation plays a 
pivotal role in G4 foldjng. One potassium ion can specifically intercalate between two G-quartet planes inside 
the G-quadruplex structure [49]. Mass spectrometry has been used to determine whether the G4 interaction 
with a given ligand results in displacement of one or more potassium ions [47]. We performed ESI-MS 
experiments with 10 µM of 24TTG, which adopts a single G4 conformation in K+. 24TTG forms a 3+1 hybrid 
conformation containing three guanine quartets, which means that two potassium ions are bound by this 
oligonucleotide. A titration revealed that the stoichiometry of the interaction between 1a and 24TTG is 2:1 
(the 3:1 complex was completely absent) and that this interaction did not result in potassium displacement 
(Figure 7). In contrast, PhenDC3 binding resulted in displacement of one potassium ion, and the major peak 
observed correspond to a complex containing one ligand and one oligonucleotide [47]. 
Our results with 1a and the human telomeric sequence 24TTG are consistent with the interaction of 
two ligands with each of the terminal G-quartets of a single G-quadruplex structure through π-π stacking as 
well as electrostatic interactions with the phosphate backbone. To confirm this hypothesis we performed 
molecular docking calculations using 1a and three different G4 scaffolds based on the crystal structures of 
(i) the parallel conformation of 22AG(1KF1) [50], (ii) the antiparallel conformation of 22CTA (2KM3) [59] and 
(iii) the hybrid conformation of 24TTG (2GKU) [60]. Indeed, we showed that 1a induced changes in CD 
signature of 22AG, 24TTG and 22CTA DNA telomeric sequences in K+ conditions that suggest a transition 
to a parallel conformation (Figure 6, Figure S3a) and that 1a significantly stabilized the parallel conformation 
adopted by F21RT (Figure 5). We docked then 1a with these three different G4 forming sequences, and the 
most favourable complex for each scaffold based on the calculated binding energy was selected 
(Supplementary Figure S4). For the parallel oligonucleotide 1KF1, the phenanthroline moiety of ligand 1a 
stacks on top of the G-quadruplex tetrad, which is consistent with π-π stacking interactions between 1a and 
a G-quartet. The positively charged amine side chains were directed towards the negatively charged 
phosphate backbones of the oligonucleotides which facilitated the electrostatic interactions required for the 
stabilization. The ligand 1a interacted with the antiparallel 22CTA (2KM3) and hybrid oligonucleotide 24TTG 
(2GKU) in a similar manner (Supplementary Figure S5, S6) and induced the parallel conformation which is 
in consistent with the CD results. As observed from the ESI-MS experiments, it is expected that another 
ligand molecule would bind at the opposite end of the quadruplex with the same mode of action. 
 
Helicase inhibition 
The aim of screening small molecules targeting G-quadruplex structures is to find strong G4 
stabilizers in order to impede key biological processes. We tested the ability of 1a to inhibit G-quadruplex 
unwinding by the Saccharomyces cerevisiae Pif1 helicase [51]. This protein can unwind G-quadruplexes in 
an ATP-driven process in the presence of magnesium. This helicase is involved in DNA replication and in 
telomerase removal from telomeric DNA [52,53]. We used the experimental conditions previously described 
[54] to compare Pif1 activity on non-G4 containing systems and G4-containing systems (Supplementary 
Scheme 1). In the present work, we used two non-G4 systems as controls: S-mut in which the G4 region 
has been replaced with sequence unable to adopt a G4 fold and S-dx, in which the G4 region has been 
replaced with a region that forms a duplex. As we experienced reproducibility issues with the opening of the 
human telomeric G-quadruplexes, we chose to analyse the ability of 1a to interfere with the helicase activity 
of Pif1 on cmyc, 25ceb, and TBA G-quadruplexes. Our results showed that 1a did not interfere with the 
helicase activity of Pif1 on single-stranded S-mut or the duplex-forming S-dx which confirm its G4 selectivity. 
In contrast, 1a dramatically impeded the resolution of G4 in the cmyc and the 25ceb systems (Figure 8). For 
tba, the presence of the ligand slightly inhibited unwinding by Pif1 (Figure 8). Our helicase assays also 
indicate that the ability of 1a to inhibit Pif1 helicase activity towards a given target is not directly correlated 
with 1a ability to stabilize the corresponding quadruplex in FRET-melting experiments. In contrast, in the 
same conditions PhenDC3 inhibits the helicase activity of Pif1 toward all the tested G4-containing systems 
[54]. Taken together, our results are in line with a better target specificity of 1a when compared to PhenDC3.  
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Cytotoxic effects on human cells 
We then tested for antiproliferative activity of ligands 1a and 1b against two human myeloid 
leukaemia cell line cultures. Against the human myeloid leukaemia cell line K562, phenanthrolines 1a and 
1b showed antiproliferative activity with IC50 of 10  0.2 and 9  0.1 M, respectively. Compound 1a also 
inhibited growth of HL60 human acute promyeloid leukemia cell line with an IC50 value of 11  0.2 M. In 
addition, compounds 1a and 1b were tested on activated (PBMNC + PHA) human peripheral blood 
mononuclear cells to evaluate their cytotoxicity on normal cells. These two derivatives 1a-b presented an 
IC50 superior to 50 μM against lymphocytes. Indexes of selectivity (IS), defined as the ratio of the IC50 value 
against the human mononuclear cells to the IC50 values against the leukaemia lines, were greater than 4.5 
for both the HL60 and the K562 cell lines. 
 
Conclusion 
We designed and synthesized ten new phenanthroline derivatives bearing polyaminoalkylbenzyl 
moieties in position 2 and/or 9. All these compounds stabilized the G-quadruplex structure formed by the 
fluorescently labelled human telomeric DNA sequence F21T. Most of the synthesized ligands displayed 
good selectivity for this G4 compared to duplex structures. We chose to study the interaction mode of the 
human telomeric DNA sequences with the promising G4 phenanthroline 1a in more detail, as 1a was the 
most potent ligand in terms of stabilization ability and selectivity. We confirmed that 1a interacted with 
oligonucleotides not labelled with dyes, inducing their stabilization and impacting their CD signatures. 
Indeed, 1a interact with DNA and RNA telomeric sequences (F21RT, 22AG, 24TTG, and 22CTA). Our data 
indicate that compound 1a significantly stabilizes and/or induces a change to a parallel-like conformation 
upon binding.  ESI-MS analyses revealed a 2:1 stoichiometry of interaction between 1a and its G4 target. 
This result and our molecular docking experiments are consistent with a π-π stacking interaction mode 
between ligand and each terminal G-quartet. Finally, we also demonstrated that our ligand interfered with 
the unwinding of the G4 structures by the Pif1 helicase. Although 1a and PhenDC3 share a common 
phenanthroline core, our results shown that the two ligands interact differently with G4 structures. In 
particular, PhenDC3 binding to telomeric sequences is accompanied by cation ejection and induction of an 
antiparallel-type CD signature, whereas 1a binding to telomeric G-quadruplexes induces a more parallel-
type CD signature and does not cause potassium ion ejection. It will be interesting to investigate the in vivo 
effects of ligand 1a as its properties in vitro suggest that it has potential in anti-cancer applications. 
Moreover, by taking into account the preliminary results and the structure-activity relationships of this new 
series, our data are a promising starting point for the further development and optimization of new and 
potent G4 ligands. 
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Experimental 
 
Chemistry 
Commercial reagents were used as received without additional purification. Melting points were determined 
with an SM-LUX-POL Leitz hot-stage microscope and are uncorrected. IR spectra were recorded on a NICOLET 380FT-
IR spectrophotometer. NMR spectra were recorded with tetramethylsilane as an internal standard using a BRUKER 
AVANCE 300 spectrometer. Splitting patterns are designated as follows: s = singlet; bs = broad singlet; d = doublet; t = 
triplet; q = quartet; dd = double doublet; ddd = double double doublet; dt = double triplet; m = multiplet. Analytical TLC 
was carried out on 0.25-mm precoated silica gel plates (POLYGRAM SIL G/UV254) with visualization of compounds by 
UV light irradiation. Silica gel 60 (70-230 mesh) was used for column chromatography. Microwave experiments were 
carried out using a focused microwave reactor (CEM Discover). High-resolution mass spectra (electrospray in positive 
mode, ESI+) were recorded on a Waters Q-TOF Ultima apparatus. Mass spectra were recorded on an Ultraflex III 
TOF/TOF system (Bruker Daltonics), equipped with 200 Hz smartbeam laser (355 nm) and operating in reflectron 
positive ion mode. Mass spectra were acquired over the m/z range 300–5000 by accumulating data from 1000 laser 
shots for each spectrum. The instrumental conditions employed to analyse molecular species were the following: ion 
source 1: 25.08 kV; ion source 2: 21.98 kV, lens: 11.03 kV, pulsed ion extraction: 30 ns, reflector: 26.39 kV, reflector 2: 
13.79 kV. Matrix suppression was activated by deflection mode: suppression up to 450 Da. Mass calibration was 
performed for each sample with a peptide calibration mixture (8206195, Peptide Calibration Standard, Bruker Daltonics). 
The instrument was controlled using Bruker's flexControl 3.4 software, and mass spectra were analysed in Bruker's 
FlexAnalysis 3.4 software. 
 
General procedure for syntheses of bis-[2,9-(formylphenyl)]-1,10-phenanthrolines 2a-c 
Method A: To a suspension of 2,9-dichloro-1,10-phenanthroline (4 mmol) and Pd(PPh3)4 (0.4 mmol) in a 
mixture of toluene/EtOH (40 mL/2 mL) under nitrogen were added K2CO3 (8.8 mmol) and 3- or 4-formylphenylboronic 
acid (8.8 mmol). The reaction mixture was refluxed for 24 h, and the cooled suspension was extracted with CH2Cl2 (3 x 
50 mL). The organic layer was washed with a saturated solution of NaCl (70 mL), and the combined organic extracts 
were dried over sodium sulfate, filtered, and evaporated under reduced pressure. The crude residue was triturated in 
ethanol. The resulting precipitate was filtered, washed with ethanol, and purified by column chromatography on silica 
gel using dichloromethane as eluent to give the pure product 2. Method B: To a suspension of 2,9-dichloro-1,10-
phenanthroline (4 mmol), 2-, 3- or 4-formylphenylboronic acid (8.8 mmol), and Pd(PPh3)4 (0.4 mmol) in DME (40 mL) 
under nitrogen were added 4 mL of a 2 M aqueous solution of Na2CO3. The reaction mixture was refluxed for 24 h. The 
suspension was then evaporated to dryness and extracted with CH2Cl2 (2 x 50 mL). The organic layer was filtered and 
washed with water (2 x 50 mL). The organic layer was dried over sodium sulfate, filtered, and evaporated under reduced 
pressure. The crude residue was triturated in ethanol. The resulting precipitate was filtered, washed with ethanol, and 
purified by column chromatography on silica gel using dichloromethane as eluent to give the pure product 2a-c. 
 
Bis-[2,9-(3-formylphenyl)]-1,10-phenanthroline 2b 
Beige crystals (71% Method A; 78% Method B); mp=181 °C. 1H NMR (CDCl3) : 10.28 (s, 2H, 2 CHO), 9.05 
(dd, J=1.45 and 1.45 Hz, 2H, 2 H-2’), 8.80 (ddd, J=7.70, 1.45 and 1.45 Hz, 2H, 2 H-6’), 8.42 (d, J=8.40 Hz, 2H, H-4 and 
H-7), 8.27 (d, J=8.40 Hz, 2H, H-3 and H-8), 8.06 (ddd, J=7.70, 1.45 and 1.45 Hz, 2H, 2 H-4’), 7.89 (s, 2H, H-5 and H-
6), 7.81 (t, J=7.70 Hz, 2H, 2 H-5’). 13C NMR (CDCl3) : 193.8 (2 C=O), 156.4 (C-2 and C-9), 147.3 (C-1a and C-10a), 
141.5 (2 C-3’), 138.6 (C-4 and C-7), 138.3 (2 C-1’), 134.6 (2 C-2’), 131.8 (2 C-5’), 131.0 (2 C-4’), 130.3 (2 C-6’), 129.6 
(C-4a and C-6a), 127.8 (C-5 and C-6), 121.1 (C-3 and C-8). HRMS-ESI m/z [M+H]+ Calcd for C26H16N2O2: 389.1290, 
Found: 389.1274. 
 
Bis-[2,9-(2-formylphenyl)]-1,10-phenanthroline 2c 
Beige crystals (70% Method B); mp=172 °C. 1H NMR (CDCl3) : 10.43 (s, 2H, 2 CHO), 8.42 (d, J=8.20 Hz, 2H, 
H-4 and H-7), 8.10 (dd, J=7.80 and 1.20 Hz, 2H, 2 H-6’), 7.99 (d, J=8.20 Hz, 2H, H-3 and H-8), 7.95 (dd, J=7.80 and 
1.20 Hz, 2H, 2 H-3’), 7.94 (s, 2H, H-5 and H-6), 7.75 (ddd, J=7.80 and 1.20 Hz, 2 H-5’), 7.60 (ddd, J=7.80 and 1.20 Hz, 
2 H-4’). 13C NMR (CDCl3) : 193.8 (2 C=O), 157.6 (C-2 and C-9), 147.2 (C-1a and C-10a), 144.6 (2 C-2’), 138.2 (C-4 
and C-7), 137.0 (2 C-1’), 134.5 (2 C-5’), 132.2 (2 C-3’), 130.5 (2 C-6’), 129.9 (2 C-4’), 129.1 (C-4a and C-6a), 128.1 (C-
5 and C-6), 125.2 (C-3 and C-8). HRMS-ESI m/z [M+H]+ Calcd for C26H16N2O2: 389.1290, Found: 389.1286. 
 
Synthesis of 2-(4-Formylphenyl)-1,10-phenanthroline 2d 
Under nitrogen, 4-formylphenylboronic acid, pinacol ester (3.5 mmol), 2-chloro-1,10-phenanthroline (4 mmol), 
Pd(PPh3)4 (0.07 mmol),  Cs2CO3 (5.8 mmol), and 1,2-dimethoxyethane (23 mL) were mixed, followed by stirring at 80 
°C for 6 h. The reaction mixture was then cooled, and water (31 mL) was added to the reaction mixture. After a stirring 
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for 10 min at 0 °C, the precipitate was removed by filtration to yield an orange solid that was then purified by column 
chromatography on silica gel using dichloromethane/methanol (90/10: v/v) as eluent to give the pure product 2d. Orange 
crystals (60%); mp=171 °C. 1H NMR (CDCl3) : 10.14 (s, 1H, CHO), 9.27 (dd, J=4.35 and 1.80 Hz, 1H, H-9), 8.53 (d, 
J=8.40 Hz, 2H, H-2’ and H-6’), 8.38 (d, J=8.40 Hz, 1H, H-4), 8.30 (dd, J=8.00 and 1.80 Hz, 1H, H-7), 8.17 (d, J=8.40 
Hz, 1H, H-3), 8.07 (d, J=8.40, 2H, H-3’ and H-5’), 7.86 (d, J=9.00 Hz, 1H, H-6), 7.83 (d, J=9.00 Hz, 1H, H-5), 7.69 (dd, 
J=8.00 and 4.35 Hz, 1H, H-8). 13C NMR (CDCl3) : 193.6 (C=O), 157.2 (C-2), 151.9 (C-9), 147.6 (C-10a), 147.5 (C-1’), 
146.5 (C-4’), 138.5 (C-4), 137.9 (C-1a), 137.7 (C-7), 131.6 (C-3’ and C-5’), 130.5 (C-6a), 129.9 (C-2’ and C-6’), 129.4 
(C-4a), 128.4 (C-5), 127.7 (C-6), 124.5 (C-8), 122.2 (C-3). HRMS-ESI m/z [M+H]+ Calcd for C19H12N2O: 285.1028, 
Found: 285.1018. 
 
General procedure for syntheses of 2,9-bis[(substituted-iminomethyl)phenyl]-1,10-phenanthrolines 3a-i 
To a solution of diamine (2.7 mmol) in ethanol (15 mL) was added bis-[2,9-(2-, 3- or 4-formylphenyl)]-1,10-
phenanthroline 2a-c (1.29 mmol). The reaction mixture was then heated under reflux for 5 h and then evaporated to 
dryness under reduced pressure. After cooling, the residue was extracted with dichloromethane (40 mL). The organic 
layer was dried over sodium sulfate and evaporated to dryness. Products were then used without further purification. 
 
2,9-Bis{4-[(3-dimethylaminopropyl)iminomethyl]phenyl}-1,10-phenanthroline 3a 
Orange oil (94%). 1H NMR (CDCl3) : 8.53 (d, J=8.40 Hz, 4H, 2 H-2’ and 2 H-6’), 8.41 (s, 2H, 2 HC=N), 8.31 
(d, J=8.40 Hz, 2H, H-4 and H-7), 8.17 (d, J=8.40 Hz, 2H, H-3 and H-8), 7.95 (d, J=8.40 Hz, 4H, 2 H-3’ and 2 H-5’), 7.79 
(s, 2H, H-5 and H-6), 3.72 (t, J=7.20 Hz, 4H, 2 NCH2), 2.42 (t, J=7.20 Hz, 4H, 2 NCH2), 2.28 (s, 12H, 4 CH3), 1.95 (qt, 
J=7.20 Hz, 4H, 2 CH2). 
 
2,9-Bis{4-[(3-(4-methylpiperazin-1-yl)propyl)iminomethyl]phenyl}-1,10-phenanthroline 3b 
Orange crystals (98%); mp=124 °C. 1H NMR (CDCl3) : 8.55 (d, J=8.40 Hz, 4H, 2 H-2’ and 2 H-6’), 8.42 (s, 
2H, 2 HC=N), 8.34 (d, J=8.40 Hz, 2H, H-4 and H-7), 8.20 (d, J=8.40 Hz, 2H, H-3 and H-8), 7.96 (d, J=8.40 Hz, 4H, 2 H-
3’ and 2 H-5’), 7.83 (s, 2H, H-5 and H-6), 3.74 (t, J=7.10 Hz, 4H, 2 NCH2), 2.62-2.40 (m, 20H, 2 NCH2 and 8 NCH2pip.), 
2.32 (s, 12H, 4 CH3), 1.97 (qt, J=7.10 Hz, 4H, 2 CH2). 
 
2,9-Bis{4-[(3-pyrrolidinopropyl)iminomethyl]phenyl}-1,10-phenanthroline 3c 
Yellow oil (98%). 1H NMR (CDCl3) : 8.56 (d, J=8.40 Hz, 4H, 2 H-2’ and 2 H-6’), 8.43 (s, 2H, 2 HC=N), 8.35 
(d, J=8.40 Hz, 2H, H-4 and H-7), 8.21 (d, J=8.40 Hz, 2H, H-3 and H-8), 7.97 (d, J=8.40 Hz, 4H, 2 H-3’ and 2 H-5’), 7.83 
(s, 2H, H-5 and H-6), 3.76 (t, J=7.20 Hz, 4H, 2 NCH2), 2.61 (t, J=7.20 Hz, 4H, 2 NCH2), 2.62-2.54 (m, 8H, 4 NCH2pyrrol.), 
2.01 (qt, J=7.20 Hz, 4H, 2 CH2), 1.85-1.79 (m, 8H, 4 CH2pyrrol.). 
 
2,9-Bis{4-[(3-morpholinopropyl)iminomethyl]phenyl}-1,10-phenanthroline 3d 
Orange oil (97%). 1H NMR (CDCl3) : 8.55 (d, J=8.40 Hz, 4H, 2 H-2’ and 2 H-6’), 8.42 (s, 2H, 2 HC=N), 8.35 
(d, J=8.40 Hz, 2H, H-4 and H-7), 8.21 (d, J=8.40 Hz, 2H, H-3 and H-8), 7.95 (d, J=8.40 Hz, 4H, 2 H-3’ and 2 H-5’), 7.83 
(s, 2H, H-5 and H-6), 3.78-3.69 (m, 12H, 4 OCH2 and 2 NCH2), 2.54-2.42 (m, 12H, 2 NCH2 and 4 NCH2morph.), 1.97 
(qt, J=7.20 Hz, 4H, 2 CH2). 
 
2,9-Bis{3-[(3-dimethylaminopropyl)iminomethyl]phenyl}-1,10-phenanthroline 3e 
Orange oil (90%). 1H NMR (CDCl3) : 8.73-8.69 (m, 4H, 2 H-2’ and 2 H-6’), 8.50 (s, 2H, HC=N), 8.37 (d, J=8.40 
Hz, 2H, H-4 and H-7), 8.27 (d, J=8.40 Hz, 2H, H-3 and H-8), 7.90 (ddd, J=7.90, 1.20 and 1.20 Hz, 2H, 2 H-4’), 7.85 (s, 
2H, H-5 and H-6), 7.69 (t, J=7.90 Hz, 2H, 2 H-5’), 3.75 (t, J=7.20 Hz, 4H, 2 NCH2), 2.42 (t, J=7.20 Hz, 4H, 2 NCH2), 
2.26 (s, 12H, 4 CH3), 1.96 (qt, J=7.20 Hz, 4H, 2 CH2). 
  
2,9-Bis{3-[(3-(4-methylpiperazin-1-yl)propyl)iminomethyl]phenyl}-1,10-phenanthroline 3f 
Orange oil (96%). 1H NMR (CDCl3) : 8.72-8.69 (m, 4H, 2 H-2’ and 2 H-6’), 8.48 (s, 2H, HC=N), 8.36 (d, J=8.40 
Hz, 2H, H-4 and H-7), 8.26 (d, J=8.40 Hz, 2H, H-3 and H-8), 7.89 (ddd, J=7.60, 1.30 and 1.30 Hz, 2H, 2 H-4’), 7.84 (s, 
2H, H-5 and H-6), 7.65 (t, J=7.60 Hz, 2H, 2 H-5’), 3.74 (t, J=7.10 Hz, 4H, 2 NCH2), 2.53-2.28 (m, 20H, 2 NCH2 and 16 
NCH2pip.), 2.29 (s, 6H, 2 CH3), 1.97 (qt, J=7.10 Hz, 4H, 2 CH2). 
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2,9-Bis{3-[(3-pyrrolidinopropyl)iminomethyl]phenyl}-1,10-phenanthroline 3g 
Yellow oil (98%). 1H NMR (CDCl3) : 8.73-8.68 (m, 4H, 2 H-2’ and 2 H-6’), 8.49 (s, 2H, HC=N), 8.36 (d, J=8.40 
Hz, 2H, H-4 and H-7), 8.26 (d, J=8.40 Hz, 2H, H-3 and H-8), 7.90 (ddd, J=7.80, 1.20 and 1.20 Hz, 2H, 2 H-4’), 7.84 (s, 
2H, H-5 and H-6), 7.68 (t, J=7.80 Hz, 2H, 2 H-5’), 3.77 (t, J=7.10 Hz, 4H, 2 NCH2), 2.61 (t, J=7.10 Hz, 4H, 2 NCH2), 
2.61-2.54 (m, 8H, 4 NCH2pyrrol.), 2.02 (qt, J=7.10 Hz, 4H, 2 CH2), 1.84-1.79 (m, 8H, 4 NCH2pyrrol.). 
 
2,9-Bis{2-[(3-dimethylaminopropyl)iminomethyl]phenyl}-1,10-phenanthroline 3h 
Orange oil (98%). 1H NMR (CDCl3) : 8.78 (s, 2H, HC=N), 8.36 (d, J=8.10 Hz, 2H, H-4 and H-7), 8.13 (dd, 
J=7.50 and 1.80 Hz, 2H, 2 H-6’), 7.91 (s, 2H, H-5 and H-6), 7.84 (dd, J=7.50 and 1.80 Hz, 2H, 2 H-3’), 7.81 (d, J=8.10 
Hz, 2H, H-3 and H-8), 7.56 (ddd, J=7.50 and 1.80 Hz, 2H, 2 H-5’), 7.50 (ddd, J=7.50 and 1.80 Hz, 2H, 2 H-4’), 3.55 (t, 
J=7.10 Hz, 4H, 2 NCH2), 2.25 (t, J=7.10 Hz, 4H, 2 NCH2), 2.18 (s, 12H, 4 CH3), 1.82 (qt, J=7.10 Hz, 4H, 2 CH2). 
 
2,9-Bis{2-[(3-(4-methylpiperazin-1-yl)propyl)iminomethyl]phenyl}-1,10-phenanthroline 3i 
Orange oil (98%). 1H NMR (CDCl3) : 8.81 (s, 2H, HC=N), 8.35 (d, J=8.40 Hz, 2H, H-4 and H-7), 8.13 (dd, 
J=7.50 and 1.50 Hz, 2H, 2 H-6’), 7.91 (s, 2H, H-5 and H-6), 7.84 (dd, J=7.50 and 1.50 Hz, 2H, 2 H-3’), 7.82 (d, J=8.40 
Hz, 2H, H-3 and H-8), 7.57 (ddd, J=7.50 and 1.50 Hz, 2H, 2 H-5’), 7.51 (ddd, J=7.50 and 1.80 Hz, 2H, 2 H-4’), 3.54 (t, 
J=6.90 Hz, 4H, 2 NCH2), 2.48-2.28 (m, 20H, 2 NCH2 and 16 NCH2pip.), 2.24 (s, 6H, 2 CH3), 1.83 (qt, J=6.90 Hz, 4H, 2 
CH2). 
 
Synthesis of 2-{4-[(3-Dimethylaminopropyl)iminomethyl]phenyl}-1,10-phenanthroline 3j 
To a solution of diamine (0.44 mmol) in ethanol (6 mL) was added 2-(4-formylphenyl)]-1,10-phenanthroline 2d 
(0.42 mmol). The reaction mixture was heated under reflux for 5 h and then evaporated to dryness under reduced 
pressure. After cooling, the residue was extracted with dichloromethane (25 mL). The organic layer was dried over 
sodium sulfate and evaporated to dryness. Products were then used without further purification. Yellow oil (97%). 1H 
NMR (CDCl3) : 9.19 (dd, J=4.40 and 1.80 Hz, 1H, H-9), 8.36 (d, J=8.40 Hz, 2H, H-2’ and H-6’), 8.33 (s, 1H, HC=N), 
8.20 (d, J=8.40 Hz, 1H, H-4), 8.16 (dd, J=8.10 and 1.80 Hz, 1H, H-7), 8.03 (d, J=8.40 Hz, 1H, H-3), 7.86 (d, J=8.40, 2H, 
H-3’ and H-5’), 7.70 (d, J=8.70 Hz, 1H, H-6), 7.67 (d, J=8.70 Hz, 1H, H-5), 7.57 (dd, J=8.10 and 4.40 Hz, 1H, H-8), 3.65 
(t, J=7.10 Hz, 4H, 2 NCH2), 2.35 (t, J=7.10 Hz, 4H, 2 NCH2), 2.21 (s, 12H, 4 CH3), 1.88 (qt, J=7.10 Hz, 4H, 2 CH2). 
  
General procedure for syntheses of 2,9-bis[(substituted-aminomethyl)phenyl]-1,10-phenanthrolines 1a-i 
 To a solution of compound 3a-i (1.26 mmol) in methanol (40 mL) was added portion-wise at 0 °C sodium 
borohydride (10.1 mmol; 8 equiv.). The reaction mixture was then heated under reflux for 4 h and then evaporated to 
dryness under reduced pressure. After cooling, the residue was triturated in water and extracted with dichloromethane 
(85 mL). The organic layer was separated, dried over sodium sulfate, and evaporated to dryness. The residue was then 
purified by column chromatography on silica gel using dichloromethane/methanol (90/10, v/v) as eluent to give the pure 
product 1. 
 
2,9-Bis{4-[(3-dimethylaminopropyl)aminomethyl]phenyl}-1,10-phenanthroline 1a 
Yellow oil (83%). 1H NMR (CDCl3) : 8.45 (d, J=8.40 Hz, 4H, 2 H-2’ and 2 H-6’), 8.32 (d, J=8.55 Hz, 2H, H-4 
and H-7), 8.16 (d, J=8.55 Hz, 2H, H-3 and H-8), 7.81 (s, 2H, H-5 and H-6), 7.56 (d, J=8.40 Hz, 4H, 2 H-3’ and 2 H-5’), 
3.95 (s, 4H, 2 NCH2), 2.77 (t, J=7.05 Hz, 4H, 2 NCH2), 2.38 (t, J=7.05 Hz, 4H, 2 NCH2), 2.31 (bs, 2H, 2 NH), 2.25 (s, 
12H, 4 CH3), 1.76 (qt, J=7.05 Hz, 4H, 2 CH2). 13C NMR (CDCl3) : 158.0 (C-2 and C-9), 147.4 (C-1a and C-10a), 143.1 
(2 C-4’), 139.6 (2 C-1’), 138.2 (C-4 and C-7), 130.0 (2 C-3’ and 2 C-5’), 129.2 (C-4a and C-6a), 129.1 (2 C-2’ and 2 C-
6’), 127.3 (C-5 and C-6), 121.3 (C-3 and C-8), 59.4 (2 NCH2), 55.1 (2 NCH2), 49.2 (2 NCH2), 46.9 (4 CH3), 29.3 (2 CH2). 
MALDI-TOF MS m/z [M+H]+ Calcd for C36H45N6: 561.371, Found: 561.425. 
 
2,9-Bis{4-[(3-(4-methylpiperazin-1-yl)propyl)aminomethyl]phenyl}-1,10-phenanthroline 1b 
Yellow oil (81%). 1H NMR (CDCl3) : 8.40 (d, J=8.40 Hz, 4H, 2 H-2’ and 2 H-6’), 8.26 (d, J=8.55 Hz, 2H, H-4 
and H-7), 8.10 (d, J=8.55 Hz, 2H, H-3 and H-8), 7.74 (s, 2H, H-5 and H-6), 7.52 (d, J=8.40 Hz, 4H, 2 H-3’ and 2 H-5’), 
3.88 (s, 4H, 2 NCH2), 2.71 (t, J=7.05 Hz, 4H, 2 NCH2), 2.60-2.29 (m, 22H, 2 NCH2, 2 NH and 8 NCH2pip.), 2.26 (s, 6H, 
2 CH3), 1.73 (qt, J=7.05 Hz, 4H, 2 CH2). 13C NMR (CDCl3) : 158.0 (C-2 and C-9), 147.4 (C-1a and C-10a), 143.1 (2 C-
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4’), 139.5 (2 C-1’), 138.3 (C-4 and C-7), 129.9 (2 C-3’ and 2 C-5’), 129.2 (C-4a and C-6a), 129.1 (2 C-2’ and 2 C-6’), 
127.3 (C-5 and C-6), 121.3 (C-3 and C-8), 58.4 (2 NCH2), 56.5 (4 NCH2pip.), 55.1 (2 NCH2), 54.6 (4 NCH2pip.), 49.4 (2 
NCH2), 47.4 (2 CH3), 28.3 (2 CH2). MALDI-TOF MS m/z [M+H]+ Calcd for C42H55N8: 671.455, Found: 671.524. 
 
2,9-Bis{4-[(3-pyrrolidinopropyl)aminomethyl]phenyl}-1,10-phenanthroline 1c 
Yellow oil (93%). 1H NMR (CDCl3) : 8.43 (d, J=8.10 Hz, 4H, 2 H-2’ and 2 H-6’), 8.26 (d, J=8.40 Hz, 2H, H-4 
and H-7), 8.12 (d, J=8.40 Hz, 2H, H-3 and H-8), 7.74 (s, 2H, H-5 and H-6), 7.53 (d, J=8.10 Hz, 4H, 2 H-3’ and 2 H-5’), 
3.91 (s, 4H, 2 NCH2), 2.74 (t, J=6.90 Hz, 4H, 2 NCH2), 2.55-2.47 (m, 12H, 2 NCH2 and 4 NCH2pyrrol.), 2.05 (bs, 2H, 2 
NH), 1.84-1.72 (m, 12H, 2 CH2 and 4 CH2pyrrol.). 13C NMR (CDCl3) : 158.0 (C-2 and C-9), 147.4 (C-1a and C-10a), 
143.1 (2 C-4’), 139.5 (2 C-1’), 138.3 (C-4 and C-7), 129.9 (2 C-3’ and 2 C-5’), 129.2 (C-4a and C-6a), 129.1 (2 C-2’ and 
2 C-6’), 127.3 (C-5 and C-6), 121.3 (C-3 and C-8), 56.2 (2 NCH2), 55.6 (4 NCH2), 55.1 (2 NCH2), 49.3 (2 NCH2), 30.5 
(2 CH2), 24.8 (4 CH2). MALDI-TOF MS m/z [M+H]+ Calcd for C40H49N6: 613.402, Found: 613.546. 
 
2,9-Bis{4-[(3-morpholinopropyl)aminomethyl]phenyl}-1,10-phenanthroline 1d 
Yellow oil (77%). 1H NMR (CDCl3) : 8.45 (d, J=8.40 Hz, 4H, 2 H-2’ and 2 H-6’), 8.34 (d, J=8.40 Hz, 2H, H-4 
and H-7), 8.17 (d, J=8.40 Hz, 2H, H-3 and H-8), 7.82 (s, 2H, H-5 and H-6), 7.57 (d, J=8.40 Hz, 4H, 2 H-3’ and 2 H-5’), 
3.96 (s, 4H, 2 NCH2), 3.73 (t, J=4.80 Hz, 8H, 4 OCH2), 2.81 (t, J=6.90 Hz, 4H, 2 NCH2), 2.54-2.42 (m, 12H, 2 NCH2 and 
4 NCH2morph.), 1.80 (qt, J=6.90 Hz, 6H, 2 NH and 2 CH2). 13C NMR (CDCl3) : 158.0 (C-2 and C-9), 147.5 (C-1a and 
C-10a), 142.9 (2 C-4’), 139.6 (2 C-1’), 138.3 (C-4 and C-7), 130.0 (2 C-3’ and 2 C-5’), 129.3 (C-4a and C-6a), 129.1 (2 
C-2’ and 2 C-6’), 127.4 (C-5 and C-6), 121.3 (C-3 and C-8), 68.4 (4 OCH2), 58.9 (2 NCH2), 55.2 (2 NCH2), 55.1 (4 
NCH2), 49.3 (2 NCH2), 27.9 (2 CH2). MALDI-TOF MS m/z [M+H]+ Calcd for C40H49N6O2: 645.392, Found: 645.469. 
 
2,9-Bis{3-[(3-dimethylaminopropyl)aminomethyl]phenyl}-1,10-phenanthroline 1e 
Yellow oil (77%). 1H NMR (CDCl3) : 8.42 (dd, J=1.40 and 1.40 Hz, 2H, 2 H-2’), 8.40 (ddd, J=7.50, 1.40 and 
1.40 Hz, 2H, 2 H-6’), 8.32 (d, J=8.40 Hz, 2H, H-4 and H-7), 8.18 (d, J=8.40 Hz, 2H, H-3 and H-8), 7.81 (s, 2H, H-5 and 
H-6), 7.57 (t, J=7.50 Hz, 2H, 2 H-5’), 7.48 (ddd, J=7.50, 1.40 and 1.40 Hz, 2H, 2 H-4’), 3.99 (s, 4H, 2 NCH2), 2.76 (t, 
J=7.20 Hz, 4H, 2 NCH2), 2.35 (t, J=7.20 Hz, 4H, 2 NCH2), 2.28 (bs, 2H, 2 NH), 2.22 (s, 12H, 4 CH3), 1.74 (qt, J=7.20 
Hz, 4H, 2 CH2). 13C NMR (CDCl3) : 158.1 (C-2 and C-9), 147.4 (C-1a and C-10a), 142.1 (2 C-3’), 140.9 (2 C-1’), 138.3 
(C-4 and C-7), 130.7 (2 C-2’), 130.3 (2 C-5’), 129.3 (C-4a and C-6a), 128.9 (2 C-4’), 127.8 (2 C-6’), 127.4 (C-5 and C-
6), 121.5 (C-3 and C-8), 59.4 (2 NCH2), 55.6 (2 NCH2), 49.2 (2 NCH2), 46.9 (4 CH3), 29.4 (2 CH2). MALDI-TOF MS m/z 
[M+H]+ Calcd for C36H45N6: 561.371, Found: 561.460. 
 
2,9-Bis{3-[(3-(4-methylpiperazin-1-yl)propyl)aminomethyl]phenyl}-1,10-phenanthroline 1f 
Yellow oil (67%). 1H NMR (CDCl3) : 8.42 (dd, J=1.30 and 1.30 Hz, 2H, 2 H-2’), 8.37 (ddd, J=7.50, 1.30 and 
1.30 Hz, 2H, 2 H-6’), 8.32 (d, J=8.40 Hz, 2H, H-4 and H-7), 8.18 (d, J=8.40 Hz, 2H, H-3 and H-8), 7.81 (s, 2H, H-5 and 
H-6), 7.56 (t, J=7.50 Hz, 2H, 2 H-5’), 7.47 (ddd, J=7.50, 1.30 and 1.30 Hz, 2H, 2 H-4’), 3.98 (s, 4H, 2 NCH2), 2.76 (t, 
J=7.10 Hz, 4H, 2 NCH2), 2.55-2.30 (m, 22H, 2 NCH2, 2 NH and 16 NCH2pip.), 2.23 (s, 6H, 2 CH3), 1.75 (qt, J=7.10 Hz, 
4H, 2 CH2). 13C NMR (CDCl3) : 158.1 (C-2 and C-9), 147.4 (C-1a and C-10a), 142.1 (2 C-3’), 140.9 (2 C-1’), 138.3 (C-
4 and C-7), 130.7 (2 C-2’), 130.3 (2 C-5’), 129.3 (C-4a and C-6a), 128.9 (2 C-4’), 127.7 (2 C-6’), 127.4 (C-5 and C-6), 
121.5 (C-3 and C-8), 58.4 (2 NCH2), 56.4 (4 NCH2pip.), 55.6 (2 NCH2), 54.6 (4 NCH2pip.), 49.5 (2 NCH2), 47.3 (2 CH3), 
28.3 (2 CH2). MALDI-TOF MS m/z [M+H]+ Calcd for C42H55N8: 671.455, Found: 671.529. 
 
2,9-Bis{3-[(3-pyrrolidinopropyl)aminomethyl]phenyl}-1,10-phenanthroline 1g  
Yellow oil (74%). 1H NMR (CDCl3) : 8.42 (dd, J=1.30 and 1.30 Hz, 2H, 2 H-2’), 8.38 (ddd, J=7.50, 1.30 and 
1.30 Hz, 2H, 2 H-6’), 8.32 (d, J=8.40 Hz, 2H, H-4 and H-7), 8.17 (d, J=8.40 Hz, 2H, H-3 and H-8), 7.80 (s, 2H, H-5 and 
H-6), 7.56 (t, J=7.50 Hz, 2H, 2 H-5’), 7.48 (ddd, J=7.50, 1.30 and 1.30 Hz, 2H, 2 H-4’), 3.99 (s, 4H, 2 NCH2), 2.77 (t, 
J=7.10 Hz, 4H, 2 NCH2), 2.56-2.45 (m, 12H, 2 NCH2 and 4 NCH2pyrrol.), 2.26 (bs, 2H, 2 NH), 1.83-1.72 (m, 12H, 2 CH2 
and 4 CH2pyrrol.). 13C NMR (CDCl3) : 158.1 (C-2 and C-9), 147.4 (C-1a and C-10a), 142.2 (2 C-3’), 140.9 (2 C-1’), 
138.3 (C-4 and C-7), 130.6 (2 C-2’), 130.3 (2 C-5’), 129.3 (C-4a and C-6a), 128.9 (2 C-4’), 127.7 (2 C-6’), 127.4 (C-5 
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and C-6), 121.5 (C-3 and C-8), 56.1 (2 NCH2), 55.6 (4 NCH2), 55.5 (2 NCH2), 49.4 (2 NCH2), 30.6 (2 CH2), 24.8 (4 CH2). 
MALDI-TOF MS m/z [M+H]+ Calcd for C40H49N6: 613.402, Found: 613.510. 
 
2,9-Bis{2-[(3-dimethylaminopropyl)aminomethyl]phenyl}-1,10-phenanthroline 1h 
Yellow-orange oil (97%). 1H NMR (CDCl3) : 8.37 (d, J=8.10 Hz, 2H, H-4 and H-7), 7.88 (s, 2H, H-5 and H-6), 
7.87 (d, J=8.10 Hz, 2H, H-3 and H-8), 7.62-7.59 (m, 2H, 2 H-6’), 7.56-7.51 (m, 2H, 2 H-3’), 7.45-7.40 (m, 4H, 2 H-4’ and 
2 H-5’), 3.65 (s, 4H, 2 NCH2), 2.36 (t, J=7.20 Hz, 4H, 2 NCH2), 1.98 (s, 12H, 4 CH3), 1.92 (t, J=7.20 Hz, 4H, 2 NCH2), 
1.23 (qt, J=7.20 Hz, 4H, 2 CH2). 13C NMR (CDCl3) : 160.9 (C-2 and C-9), 146.6 (C-1a and C-10a), 142.6 (2 C-2’), 139.7 
(2 C-1’), 138.0 (C-4 and C-7), 132.9 (2 C-3’), 131.5 (2 C-5’), 130.0 (2 C-6’), 128.8 (C-4a and C-6a), 128.6 (2 C-4’), 127.6 
(C-5 and C-6), 125.1 (C-3 and C-8), 59.1 (2 NCH2), 53.1 (2 NCH2), 48.1 (2 NCH2), 46.7 (4 CH3), 28.2 (2 CH2). MALDI-
TOF MS m/z [M+H]+ Calcd for C36H45N6: 561.371, Found: 561.384. 
 
2,9-Bis{2-[(3-(4-methylpiperazin-1-yl)propyl)aminomethyl]phenyl}-1,10-phenanthroline 1i 
Yellow oil (98%). 1H NMR (CDCl3) : 8.35 (d, J=8.10 Hz, 2H, H-4 and H-7), 7.88 (d, J=8.10 Hz, 2H, H-3 and 
H-8), 7.87 (s, 2H, H-5 and H-6), 7.62-7.59 (m, 2H, 2 H-6’), 7.55-7.50 (m, 2H, 2 H-3’), 7.45-7.40 (m, 4H, 2 H-4’ and 2 H-
5’), 3.66 (s, 4H, 2 NCH2), 2.45-2.15 (m, 22H, 2 NCH2, 2 NH and 16 NCH2pip.), 2.18 (s, 6H, 2 CH3), 2.00 (t, J=6.90 Hz, 
4H, 2 NCH2), 1.29 (qt, J=6.90 Hz, 4H, 2 CH2). 13C NMR (CDCl3) : 161.0 (C-2 and C-9), 146.7 (C-1a and C-10a), 142.5 
(2 C-2’), 141.7 (2 C-1’), 137.9 (C-4 and C-7), 132.8 (2 C-3’), 131.5 (2 C-5’), 129.9 (2 C-6’), 128.7 (C-4a and C-6a), 128.5 
(2 C-4’), 127.6 (C-5 and C-6), 125.1 (C-3 and C-8), 58.0 (2 NCH2), 56.4 (4 NCH2pip.), 54.4 (4 NCH2pip.), 53.1 (2 NCH2), 
48.2 (2 NCH2), 47.4 (2 CH3), 27.6 (2 CH2). MALDI-TOF MS m/z [M+H]+ Calcd for C42H55N8: 671.455, Found: 671.502. 
 
2-{4-[(3-Dimethylaminopropyl)aminomethyl]phenyl}-1,10-phenanthroline 1j 
To a solution of compound 3j (0.4 mmol) in methanol (6 mL) was added portion-wise at 0 °C sodium 
borohydride (1.6 mmol; 4 equiv.). The reaction mixture was heated under reflux for 3 h and then evaporated to dryness 
under reduced pressure. After cooling, the residue was extracted with dichloromethane (25 mL). The organic layer was 
dried over sodium sulfate and evaporated to dryness to give 1j. This product was then used without further purification. 
Yellow oil (95%). 1H NMR (CDCl3) : 9.20 (dd, J=4.20 and 1.80 Hz, 1H, H-9), 8.29 (d, J=8.40 Hz, 2H, H-2’ and H-6’), 
8.23 (d, J=8.40 Hz, 1H, H-4), 8.20 (dd, J=8.10 and 1.80 Hz, 1H, H-7), 8.05 (d, J=8.40 Hz, 1H, H-3), 7.75 (d, J=8.70 Hz, 
1H, H-6), 7.70 (d, J=8.70 Hz, 1H, H-5), 7.60 (dd, J=8.10 and 4.20 Hz, 1H, H-8), 7.47 (d, J=8.40, 2H, H-3’ and H-5’), 
3.86 (s, 2H, NCH2), 2.68 (t, J=7.20 Hz, 2H, NCH2), 2.32 (t, J=7.20 Hz, 2H, NCH2), 2.21 (s, 6H, 2 CH3), 1.69 (qt, J=7.20 
Hz, 2H, CH2). 13C NMR (CDCl3) : 158.7 (C-2), 151.6 (C-9), 147.7 (C-10a), 147.4 (C-4’), 143.0 (C-1a), 139.7 (C-1’), 
138.2 (C-4), 137.5 (C-7), 130.4 (C-6a), 129.9* (C-3’ and C-5’), 129.4 (C-2’ and C-6’), 128.8 (C-4a), 127.7 (C-5), 127.5 
(C-6), 124.2 (C-8), 121.9 (C-3), 59.4 (NCH2), 55.1 (NCH2), 49.1 (NCH2), 46.9 (2 CH3), 29.3 (CH2). MALDI-TOF MS m/z 
[M+H]+ Calcd for C24H26N4: 370.216, Found: 371.088. 
 
General procedure for preparation of 2,9-bis[4-(substituted-aminomethyl)phenyl]-1,10-phenanthrolines and 2-{4-[(3-
Dimethylaminopropyl)aminomethyl]phenyl}-1,10-phenanthroline oxalate salts 
To a solution of compounds 1a-j (1 mmol) in isopropanol (35 mL) was added oxalic acid (8 or 4 mmol). The 
reaction mixture was heated under reflux for 30 min. The precipitate was filtered, washed with isopropanol then with 
diethyl ether and dried under reduced pressure to give the ammonium salts of 1a-j. 
 
X-ray data 
The structure of compound 2b was established by X-ray crystallography (Figure 2). A colourless single crystal 
of 2b was obtained by slow evaporation from a methanol/chloroform solution (v/v : 20/80) : triclinic, space group P21/c, 
a=3.85830(10) Å, b=27.5209(11) Å, c=17.5367(7) Å, =90°, =91.0803(17)°, =90°, V=1861.78(12)Å3, Z=4, (calcd)= 
1.450 Mg.m-3, FW=406.42 for C26H16N2O2H2O, F(000)=848. Full crystallographic results have been deposited at the 
Cambridge Crystallographic Data Centre (CCDC-1439636), UK, as supplementary material [55]. The data were corrected 
for Lorentz and polarization effects and for empirical absorption correction[56]. The structure was solved by direct 
methods and refined using Shelx 2013 suite of programs[56]. 
 
Solubility of compounds 
Stock solutions of all compounds were prepared at 2 mM and stored at -20 °C. When compounds were not 
soluble in DMSO at this concentration, the derivatives were diluted in water. 
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Oligonucleotides 
Synthetic oligonucleotides used in this study were purchased from Eurogentec. Stock solutions were prepared 
in water at concentrations between 100 and 500 µM and stored at -20 °C. Concentrations were determined by 
quantification of absorbance at 260 nm and using the molar coefficient extinction provided by the manufacturer. The 
sequences used are listed in Supplementary Table 1. All nucleotides were folded before use in all experiments, typically 
in the salts conditions indicated, by heating for 5 min at 90 °C and then either slow cooling to room temperature or quick 
cooling on ice. 
 
FRET melting assays 
 The FRET melting method is based on the fluorescence resonance energy transfer (FRET) phenomenon 
between two dyes: a donor and an acceptor (here: 5' FAM and 3' TAMRA). When the nucleotides are folded at low 
temperature the fluorescence emission of the donor will be minimal due to the acceptor proximity. Fluorescence 
emission recovery will occur when temperature is increased during the thermally induced melting of the structure. 
Fluorescence recording was performed in a Strategene MX3005P real-time PCR device at temperatures from 25 to 90 
°C using a 492-nm excitation wavelength and a 516-nm detection wavelength. Experiments were performed in 96-well 
plates, and each condition was tested in duplicate. In each well, 200 nM of labelled oligonucleotide was melted in the 
presence (or not) of the ligand with (or without) the competitor at concentrations specified. 
To determine whether the ligands stabilized the G-quadruplex conformations, we determine the temperature 
of half denaturation of the G4 in the absence and in the presence of increasing ligand concentrations. For this 
experiment we used F21T. The oligonucleotide was prefolded in 10 mM lithium cacodylate buffer (pH 7.2), with either 
10 mM KCl and 90 mM LiCl (K+ condition) or 100 mM NaCl (Na+ condition) as previously described [57]. The salt 
conditions of the experiment were similar to the one used for the G4 prefolding. In addition to the labelled 
oligonucleotide, the wells contained 0, 1, 2, or 5 µM ligand. To determine ligand G4 vs. duplex selectivity, an unlabelled 
DNA competitor ds26 was used. The G4 versus duplex selectivity experiments were performed in K+ conditions using 
F21T. Wells contained F21T, 1 µM ligand, and 0, 3, or 10 µM unlabelled competitor ds26. Finally, in order to identify a 
putative preferred G4 conformation targeted by a ligand, a set of oligonucleotides covering a range of possible G4 
conformations was used [40]. For the RNA, the KCl concentration was 1 mM and the LiCl concentration was 99 mM [46].  
 
Circular dichroism (CD) spectroscopy 
CD was employed to assess conformational changes induced by ligand binding. Melting experiments were 
also performed with unlabelled sequences to exclude direct dye-ligand interactions. CD experiments were performed 
on a Jasco J-815 device. CD spectra were the average of three scans, recorded in the wavelength range 230-335 nm 
at 20 °C at a scan speed of 50 nm/min. The response time was 1 sec, the data pitch was 0.5 nm and the band width 
was fixed at 2 nm. Buffer conditions were 10 mM lithium cacodylate (pH 7.2), either with 10 mM KCl and 90 mM LiCl 
(K+ conditions) or 100 mM NaCl (Na+ conditions) concentrations. The CD spectrum of the buffer alone was subtracted 
from each spectrum. The DNA concentration was 3 µM and titrations were performed adding 1 to 5 eq of the ligand 
under investigation. 
For melting experiments, oligonucleotides were prefolded by heating for 5 min at 90 °C and then slowly cooling 
to room temperature without ligand or with the indicated amount of the ligand. The temperature range for the melting 
analysis was 4 to 95 °C, and the heating rate was 1 °C/min.  Changes in the CD signal between 230 and 335 nm were 
followed at a scan speed of 100 nm/min and with a data pitch of 0.2 nm. Each melting experiment was performed at 
least 3 times. 
 
 
Mass spectrometry 
The stoichiometry was obtained by electrospray-mass spectrometry in negative ion mode on a Waters LCT 
Premier mass spectrometer. The ESI source voltage was 2.2 kV, and the sample cone voltage 200 V. The source 
temperature was set to 60 °C. The source voltage was increased to 45 mbar and measured using a Center Two probe 
(Oerlinkon Leybold Vacuum). The syringe injection flow rate is 200 µL/h. These parameters ensured a good signal 
intensity without disruption of the non-covalent complexes. Note that K+/DNA or Ligandn+/DNA complexes or adducts 
do not disrupt easily upon collision-induced activation. Trimethylammonium acetate (TMAA, Ultra for UPLC, Fluka) and 
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potassium chloride (KCl, >99.99%, Sigma) were purchased from Sigma-Aldrich. The injected solutions were prepared 
diluting the proper volume of the oligonucleotide stock solutions to reach 10 µM DNA, 100 mM TMAA, and 1 mM KCl 
supplemented by the mentioned amount of ligand. An annealing at 85 °C followed by a cooling to room temperature 
was done 24 h before the mass spectrometry experiments.  
 
Fluorescent-based helicase assay using Pif1 from Saccharomyces cerevisiae 
This assay was used to assess the ability of putative G4 ligands to interfere with the helicase activity of Pif1. 
This assay was performed using Tecan Infinite M1000PRO micro-plate reader device in black 96-wells plates (Greiner 
Bio-one). Buffer conditions were 20 mM Tris-HCl (pH 7.2), 5 mM MgCl2, 1 mM KCl, and 99 mM NaCl. In this assay, the 
state of a FAM-Dabcyl labelled oligonucleotide system is followed as it is directly correlated to the helicase activity of 
Pif1. Each oligonucleotide system is composed of a single-stranded region (here including 11 adenosines) that is 
required for the 5’ to 3’ Pif1 activity, a central G-quadruplex, and a labelled duplex. Experiments were carried out at 25 
°C using 492-nm excitation wavelength and 520-nm emission wavelength to follow the FAM fluorescence emission. 
Each experiment was performed at least three times. In each well, 20 nM of Pif1 was added to 40 nM DNA, and 5 µM 
ATP with or without 1 µM ligand as previously described [54]. The oligonucleotides are listed in Supplementary Table 1 
and included dabcyl-labelled S-mut, S-dx, S-cmyc, S25ceb, and S-tba.  Ss-FAM is a short single-stranded FAM-labelled 
oligonucleotide that is complementary to the 3’-most 15 nucleotides of the dabcyl-labelled strand. We also used the 
complementary non-labelled oligonucleotides of each of the dabcyl-labelled oligonucleotide to trap them. 
 
Biology 
Cell culture 
The K562 and HL60 cells were grown in RPMI 1640 medium (Life Technology) supplemented with 10% fetal 
calf serum, antibiotics (100 U/mL penicillin, 100 µg/mL streptomycin), and L-glutamine (Eurobio) at 37 °C, 5% CO2 in 
air. The cytotoxicities of G4 ligands were also evaluated in freshly isolated normal human peripheral blood mononuclear 
cells activated with phytohemagglutinin (PHA). Blood from healthy volunteers was centrifuged through a Ficoll gradient 
to isolate mononuclear cells. Cells were then incubated in medium alone or induced to enter cell cycle by the addition 
of PHA (5 µg/mL, Murex Biotech Limited). 
Cytotoxicity test 
The MTS cell proliferation assay (Promega) is a colorimetric assay that measures the reduction of the 
tetrazolium MTS into formazan by the mitochondria of viable cells. Cells were washed twice in PBS and plated in 
quadruplicate into microtiter plate wells in 100 L culture media with or without G4 ligand at concentrations of 1, 5, 10, 
20, and 50 M for 3 days. After 3 hours of incubation at 37 °C with 20 L MTS per well, the plates were read using an 
ELISA microplate reader (Thermo, Electrocorporation) at 490 nm. The amount of colour produced was directly 
proportional to the number of viable cells. The results are expressed as the concentrations inhibiting cell growth by 50% 
after a 3 day incubation period. The IC50 was determined by linear regression analysis (Microsoft Excel) and is 
expressed in μM ± SD. 
 
Molecular docking: 
 Molecular docking was performed using Autodock (Version 4.2) docking software. The molecular structure of 
1a was optimized by DFT calculations using the Gaussian 03 program at the B3LYP level of theory and 6-31G (d,p) 
basis set. Autodock Tools was used to generate the pdbqt files required for both the DNA and the complex. All the polar 
hydrogens were added, and non-polar hydrogens emerged from the structure. The DNA structure was kept rigid during 
the docking while the ligand was allowed to have rotatable bonds. The DNA motif was enclosed in the grid box defined 
by Auto Grid (dimensions 40" × 40" × 40" Å) used for dispersion/repulsion, hydrogen bonding, electrostatics, and 
desolvation. Auto Grid performed a pre-calculated atomic affinity grid map for each atom type in the ligand plus an 
electrostatic map and a separate desolvation map for the substrate molecule. Then, during the AutoDock calculation, 
the energetics of a particular ligand configuration was evaluated using the values from the grids. Ligand docking was 
carried out with the AutoDock 4.2 Lamarckian Genetic Algorithm (LGA) with an initial population of 150 randomly placed 
individuals, a maximum number of 25×10 6 energy evaluations, and a probability of performing local search on individual 
of 0.15. The results of 150 independent docking runs were clustered with a RMSD of 5.0 Å. Other parameters were set 
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as default. The selected docking solution was the most energetically favourable from the most populated cluster. The 
most stabilized nucleoside-DNA complex structure was imaged using Chimera 1.11.2 software. 
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Figure 2. The ORTEP drawing of bis-[2,9-(3-formylphenyl)]-1,10-phenanthroline 2b with thermal ellipsoids at 30% level. 
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 Figure 3. Stabilization of F21T (0.2 µM) by compounds 1a-j (1 µM). Comparison of ΔT(1/2) in K+ conditions vs. ΔT(1/2) in 
Na+ conditions. Dashed line represents an equal stabilization in K+ and Na+ conditions. In K+, the T(1/2) in the absence 
of ligand is 52.2 ± 0.8 °C and that in Na+ is 49.4 ±1 .0 °C 
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Figure 4. Stabilization of F21T (0.2 µM) by 1a-g (1 µM) in the presence of ds26. Comparison of ΔT1/2 in K+ conditions 
in absence of competitor vs. ΔT(1/2) in K+ conditions in presence of competitor ds26. Dark grey bars represent the F21T 
ΔT1/2 with 1 µM ligand, light grey bars represent F21T ΔT1/2 in presence of with 1 µM ligand and 15 eq of ds26, and 
white bars represent F21T ΔT1/2 in presence of with 1 µM ligand and 50 eq excess of ds26. 
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Figure 5. Stabilization specificity profile of 1a (1 µM) toward a chosen panel of oligonucleotides that adopt different 
conformations. The difference in T1/2 with and without 0.2 μM 1a, ΔT1/2, in °C is plotted. Experiments were performed in 
10 mM lithium cacodylate buffer (pH 7.2), 90 mM LiCl, and 10 mM KCl. FdxT is a duplex (T1/2 without ligand = 67.6±0.3 
°C), F25cebT (T1/2 = 69.3±0.4 °C) and FmycT (T1/2 = 66.3 ± 0.9 °C) adopt parallel G4 conformations. FctaT (T1/2 = 58.8 
± 0.2°C), Fbom17T (T1/2 = 49.7 ± 0.8 °C) and FtbaT (T1/2  = 52.9 ± 0.7 °C) adopt antiparallel conformations. F21T (T1/2 
= 52.2 ± 0.8 °C) adopts a mix of antiparallel and hybrid conformations. The RNA F21RT (T1/2 = 56.2 ± 0.7 °C) was 
assessed in 10 mM lithium cacodylate buffer (pH 7.2), 99 mM LiCl, and 1 mM KCl; it adopts a parallel conformation.   
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Figure 6. CD titration of (a) 22AG (3 µM) and (b) 24TTG (3 µM) with 1a. CD spectra were recorded in 10 mM lithium 
cacodylate buffer (pH 7.3), 90 mM LiCl, and 10 mM KCl. Solid lines correspond to the CD profile in the absence of 1a, 
dotted black lines correspond to the spectra after sequential additions of 4 equivalents of 1a one equivalent at a time, 
and grey dotted lines correspond to the CD profile in the presence of 5 equivalents of 1a. 
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 Figure 7. Electrospray mass spectrometry titration of 24TTG (10 µM) with ligand 1a. All spectra were recorded in 100 
mM TMAA and 1 mM KCl in presence of the indicated amount of 1a (from 0 to 5 equivalents as compared to the DNA 
concentration). 
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Figure 8. Fluorescence-based helicase assay with 1a and substrates containing indicated control (S-Mut and S-dx) or 
G4-forming regions from cmyc, ced, and tba. Black: without 1a, grey: with 1a. 
 
 
 
 
 
  
 28
Table 1. Physical properties of 1a-j oxalates. 
 
Compound  Salt[a] mp (°C)[b] % 
Yield[c] 
1a Beige crystals 4 (COOH)2 202 87 
1b Beige crystals 6 (COOH)2 > 240 78 
1c Yellow crystals 4 (COOH)2 197 79 
1d Pale-yellow crystals 4 (COOH)2 > 240 62 
1e Pale-orange crystals 4 (COOH)2 232 62 
1f Pale-yellow crystals 6 (COOH)2 220 76 
1g Beige crystals 4 (COOH)2 171 82 
1h Beige crystals 4 (COOH)2 96 74 
1i Beige crystals 6 (COOH)2 168 80 
1j Pale-orange crystals 2 (COOH)2 141 88 
 
[a]The stoichiometries and compositions of the salts were determined by elemental analyses (within ±0.4% of the theoretical values). 
[b]Crystallization solvent: 2-PrOH–H2O. 
[c]The yields only include the conversions into the ammonium oxalates. 
 
 
 
 
 
 
Table 2. FRET-melting values for PhenDC3 and compounds 1a-j with F21T in K+ conditions. 
 
Compound                  F21T Δ T(1/2) °C [a] Selectivity index [b]  
PhenDC3 21.8±0.5 0.99±0.0 
1a 14±1.7 0.92±0.2 
1b 14.9±1.5 0.82±0.1 
1c 10.4±1.6 0.88±0.2 
1d 11.2±1.1 0.93±0.1 
1e 9.4±2.2 0.89±0.3 
1f 11.6±1.7 0.87±0.2 
1g 9.6±1.4 0.86±0.2 
1h 5.3±1.2 nd [c] 
1i 7.7±1.0 nd 
1j 5.9±1.6 nd 
 
[a]ΔT1/2 (°C) of F21T (0.2 µM) is reported at 1 µM ligand concentration in 10 mM lithium cacodylate (pH 7.2), 10 mM KCl 
and 90 mM LiCl. PhenDC3 was used as control compound. F21T ΔT1/2 in K+ = 52.2 ± 0.8 °C. 
[b]Selectivity index in K+ conditions for 1 µM of each compound was based on the ratio between F21T ΔT1/2 in presence 
of 3 µM of ds26 and F21T ΔT1/2 in absence of competitor. 
[c] nd= not determined for compounds exhibiting a low (<10 °C) stabilisation at 1 µM ligand concentration in K+ conditions.  
 
 
 
 
 
 
 
 
 
 
 
